Blueprint Medicines' net profit under GAAP for 9 months of 2020 was $399.55 million, against a loss of $281.363 million in the previous year. Revenue increased 49.7 times to $759.629 million, against $14.979 million in the previous year.
Blueprint Medicines' net profit under GAAP for 9 months of 2020 was $399.55 million, against a loss of $281.363 million in the previous year. Revenue increased 49.7 times to $759.629 million, against $14.979 million in the previous year. 
ir.blueprintmedicines.com
English (US) 